GC Biopharma Corp. (KRX:006280)
South Korea · Delayed Price · Currency is KRW 129,900
+3,400 (2.69%)
Aug 7, 2026, 3:30 PM KST
GC Biopharma Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,043,032 | 1,991,279 | 1,679,892 | 1,626,644 | 1,711,313 | 1,537,826 |
Revenue Growth | 19.70% | 18.54% | 3.27% | -4.95% | 11.28% | 2.24% |
Gross Profit Gross Profit Growth | 562,641 | 552,642 | 480,544 | 483,331 | 579,962 | 519,240 |
Operating Income Operating Income Growth | 71,582 | 67,809 | 32,039 | 33,911 | 80,710 | 73,726 |
Net Income Net Income Growth | -13,896 | -4,674 | -26,280 | -26,632 | 65,453 | 123,212 |
Earnings Per Share EPS Growth | -1217.98 | -410.00 | -2303.00 | -2333.42 | 5734.87 | 10795.57 |
EPS Growth | - | - | - | - | -46.88% | 52.02% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Manufacturing and Sales of Pharmaceuticals, Etc. Manufacturing and Sales of Pharmaceuticals, Etc. Growth | 2,024,267 | 1,982,541 | 1,580,983 | 1,440,879 | 1,484,485 |
Diagnosis and Analysis of Samples, Etc. Diagnosis and Analysis of Samples, Etc. Growth | 172,972 | 181,902 | 200,119 | 213,763 | 262,178 |
Other Other Growth | 17,855 | 14,146 | 16,061 | 18,496 | 22,095 |
Consolidation Adjustment Consolidation Adjustment Growth | -172,062 | -187,310 | -117,271 | -46,494 | -57,445 |
Total Total Growth | 2,043,032 | 1,991,279 | 1,679,892 | 1,626,644 | 1,711,313 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 42,727 | 50,804 | 23,995 | 55,506 | 112,306 | 202,935 |
Total Debt Total Debt Growth | 914,327 | 982,144 | 828,142 | 724,022 | 575,543 | 606,574 |
Net Cash (Debt) Net Cash Growth | -871,600 | -931,340 | -804,147 | -668,516 | -463,238 | -403,639 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -76367.15 | -81602.53 | -70458.10 | -58574.02 | -40587.96 | -35366.01 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 161,144 | 99,463 | -53,460 | -5,473 | 119,154 | 125,979 |
Capital Expenditures CapEx Growth | -95,382 | -72,362 | -31,992 | -79,087 | -57,996 | -102,321 |
Free Cash Flow Free Cash Flow Growth | 65,762 | 27,101 | -85,452 | -84,560 | 61,158 | 23,658 |
Free Cash Flow Growth | - | - | - | - | 158.51% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 27.54% | 27.75% | 28.61% | 29.71% | 33.89% | 33.77% |
Operating Margin | 3.50% | 3.40% | 1.91% | 2.08% | 4.72% | 4.79% |
Pretax Margin | -1.15% | -1.77% | -2.45% | -1.67% | 5.01% | 11.22% |
Profit Margin | -0.68% | -0.24% | -1.56% | -1.64% | 3.82% | 8.01% |
FCF Margin | 3.22% | 1.36% | -5.09% | -5.20% | 3.57% | 1.54% |
| Fiscal Year | Current | FY 2025 |
|---|---|---|
| Period Ending | Aug '26 Aug 8, 2026 | Dec '25 Dec 31, 2025 |
Dividend Per Share Dividend Per Share Growth | 1500.000 | 1500.000 |
Dividend Per Share Growth | 0% | - |
Dividend Yield | 1.15% | 0.95% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 22.58 | 20.19 |
Forward PE | 5.95 | 28.99 | 87.99 | 47.35 | 21.09 | 25.00 |
P/FCF Ratio | 22.54 | 66.96 | - | - | 24.17 | 105.17 |
PS Ratio | 0.73 | 0.91 | 1.22 | 0.88 | 0.86 | 1.62 |